Form 4: Arcus Biosciences President Sells Shares

Arcus Biosciences President Juan C. Jaen sold 4,314 shares of common stock for approximately $20.32 per share under a pre-arranged trading plan.

Summary

• Juan C. Jaen, President of Arcus Biosciences, Inc. (RCUS), reported the sale of common stock.
• The transaction involved the disposition of 4,314 shares of common stock.
• The shares were sold on October 30, 2025, at a weighted average price of $20.3175 per share.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2024.
• The selling price for the shares ranged from $20.12 to $20.63 per share.
• Following the transaction, Jaen beneficially owns 1,087,060 shares indirectly through a Trust and 367,220 shares directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While insider selling can be a bearish signal, the execution under a pre-arranged Rule 10b5-1 plan mitigates concerns about opportunistic trading, suggesting a planned financial move rather than a reaction to new, undisclosed negative information.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned disposition for personal financial management rather than an immediate reaction to new, undisclosed information. This reflects good corporate governance and transparency.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it might suggest a lack of confidence in the company's future prospects, although no specific reason for the sale beyond the plan is provided.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, potentially leading to minor negative sentiment, though this is mitigated by the disclosure of a pre-arranged 10b5-1 plan.

Key Dates

Recommendation

While insider selling can sometimes be a bearish signal, this transaction was conducted under a pre-arranged 10b5-1 plan, which typically indicates a planned financial move rather than a reaction to new, material non-public information. Without additional context on the company's performance or other market factors, this single Form 4 filing alone does not provide sufficient grounds for a strong buy or sell recommendation, thus a 'hold' stance is appropriate.

Keywords

Arcus Biosciences, RCUS, Juan C. Jaen, insider trading, Form 4, stock sale, 10b5-1 plan, officer transaction, common stock